Your AI-Trained Oncology Knowledge Connection!

Yael Cohen, MD

Articles

Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for Myeloma

January 28th 2022

Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.

$Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.$

Yael Cohen, MD, on the Safety Profile of Cilta-Cel in Refractory Myeloma

Yael Cohen, MD

January 27th 2022

Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

$In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.$

Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma

Yael Cohen, MD

January 24th 2022

In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.

Yael Cohen, MD, on Promising Therapeutics in the Heavily Pretreated Myeloma Space

Yael Cohen, MD

January 19th 2022

Yael Cohen, MD, sat down with CancerNetwork® to spotlight a number of promising treatments that are under investigation for patients with heavily-pretreated multiple myeloma.

$CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma$

Yael Cohen, MD, on Background for and Key Findings from the Updated CARTITUDE-2 Trial With Cilta-Cel in Refractory Myeloma

Yael Cohen, MD

January 18th 2022

CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma